Analysis for WST

📈 Growth & Financial Trajectory

Over the eight quarters from 2024 Q3 to 2026 Q2, West Pharmaceutical Services shows an overall revenue lift from $746.9M to $872.3M, a gain of about +16.8%. Net income attributable to parent rises from $136.0M to $154.0M (+13%), despite a mid-cycle dip in 2025 Q1 when revenues dropped to roughly $698–$705M and earnings softened. Gross margin expands from around 35.5% to the high-30s, roughly 37% by 2026, signaling improving utilization and pricing power.

The trend is not perfectly smooth—2025 quarters show volatility in revenue and earnings—but by 2026 the company sustains profitability at higher absolute levels than the start of the period.

💰 Margins & Cash Flow

• Gross Margin moved from the mid-30s toward the high-30s, roughly 35–38% across the period, supporting operating margins around ~20% in several quarters (e.g., Q3 2024 ~21.6%, Q2 2026 ~20.5%).
• Cash flow from operations remained positive across quarters (examples: Q1 2025 $129.4M, Q2 2026 $124.0M), while investing/financing cash flows were typically negative, reflecting ongoing capex and capital management.

🛡️ Balance Sheet & Liquidity

• Equity attributable to parent ranges around $2.99B–$3.18B; Total assets hover near $3.6B–$4.1B.
• Long-term debt is modest, around $202.6M–$202.9M, with current liabilities generally under $0.7B, yielding a healthy liquidity profile and robust balance sheet.

⚠️ Key Drivers & Risks

• Drivers: Pharma outsourcing growth; rising demand for pharmaceutical packaging and containment.
• Risks: Cyclicality of healthcare capex and sensitivity to gross-margin pressures; currency and input-cost volatility could compress margins.